alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.2920 Clinical mercury thermometer. ( a ) *Identification.* A clinical mercury thermometer is a device used to measure oral, rectal, or axillary (armpit) body temperature using the thermal expansion of mercury.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 63 FR 59228, Nov. 3, 1998]
# C_2015228EN.01002604.xml

| 13.7.2015 | EN | Official Journal of the European Union | C 228/26 |
| --- | --- | --- | --- |

13.7.2015

EN

Official Journal of the European Union

C 228/26

---

Order of the General Court of 8 May 2015 — Grupo Bimbo v OHIM (Form of round sandwich bread)

(Case T-542/14) (1)

1

(2015/C 228/38)

Language of the case: Spanish

The President of the Third Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 339, 29.9.2014.

1

---
- USGS Home
- Contact						   USGS
- Search 
USGS

- mobile menu barsUSGS Publications Warehouse
    Contact
    Explore recent publications 
    by USGS							   Authors
    Browse all of Pubs Warehouse 
    by							   Publication type and year
    FAQS
    Web 
    Service Documentation
    Other 
    Resources
    Descriptions of US 
    Geological Survey Report							   Series
- USGS Publications Warehouse
- Contact
- Explore recent publications 
    by USGS							   Authors
- Browse all of Pubs Warehouse 
    by							   Publication type and year
- FAQS
- Web 
    Service Documentation
- Other 
    Resources
- Descriptions of US 
    Geological Survey Report							   Series

- USGS Publications 
  Warehouse
- Explore					    
  Explore recent publications 
    by USGS							   Authors
    Browse all of Pubs Warehouse 
    by							   Publication type and year
- Explore recent publications 
    by USGS							   Authors
- Browse all of Pubs Warehouse 
    by							   Publication type and year
- Documentation					    
  FAQS
    Web 
    Service Documentation
    Other 
    Resources
    Descriptions of US 
    Geological Survey Report							   Series
- FAQS
- Web 
    Service Documentation
- Other 
    Resources
- Descriptions of US 
    Geological Survey Report							   Series
- Contact

### Geology of the Marathon region, Texas

#### Professional Paper 187

Tweet


#### Links

- More information: **National Geologic Map Database Index Page**     
                             (html)
- Document: **Document**                                 
  (34685 pdf)
- Plates:
- **Plate 16**                                 
    (3056 pdf)
- **Plate 21**                                 
    (6092 pdf)
- **Plate 23**                                 
    (8582 pdf)
- **Plate 24**                                 
    (7786 pdf)
- Download citation as:  RIS

#### Abstract

#### Additional publication details

Part or all of this report is presented in Portable 
Document Format (PDF). For best results viewing and printing PDF documents, it 
is recommended that you download the documents to your computer and open them 
with Adobe Reader. PDF documents opened from your browser may not display or 
print as intended. Download the latest version of Adobe 
Reader, free of charge. More information about viewing, downloading, and 
printing report files can be found here.

Accessibility
				    FOIA				    Privacy				    Policies and					   
Notices

U.S. Department of the					   Interior |				    
U.S. Geological 
Survey				   URL: http://pubs.er.usgs.gov/publication/pp187 
                    				   Page Contact Information: Pubs 
Warehouse Contact				   Page				   Page Last Modified: February 02, 2012 
00:10:36
#### § 558.555 Semduramicin.

(a) *Specifications.* Type A medicated article containing:

(1) 22.7 grams (g) per pound (lb) (50 g/kilogram (kg)) semduramicin (as semduramicin sodium).

(2) 22.7 g/lb (50 g/kg) semduramicin (as semduramicin sodium biomass).

(b) *Sponsor.* See No. 066104 in § 510.600(c) of this chapter for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section; for use of product described in paragraph (a)(2) of this section as in paragraph (e) of this section.

(c) *Related tolerances.* See § 556.597 of this chapter.

(d) *Conditions of use in chickens.* It is used in chicken feed as follows:

| Semduramicin in grams per ton | Combinations in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (1) 22.7 (25 ppm) | | Broiler chickens: For the prevention of coccidiosis caused by *Eimeria acervulina, E. brunetti, E. maxima, E. mivati*/*E. mitis, E. necatrix*, and *E. tenella.* | Do not feed to laying hens. | 066104 |
| (2) 22.7 | Bacitracin methylenedisalicylate 10 to 50 | Broiler chickens: As in paragraph (d)(1) of this section; for improved feed efficiency. | Feed continuously as sole ration. Do not feed to laying hens. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter. | 066104 |

(e) *Conditions of use in chickens.* It is used in chicken feed as follows:

| Semduramicin in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (1) 22.7 (25 ppm) | | Broiler chickens: For the prevention of coccidiosis caused by *Eimeria tenella, E. acervulina, E. maxima, E. brunetti, E. necatrix, and E. mitis.* | Do not feed to laying hens. | 066104 |
| (2) [Reserved] | | | | |

(f) Semduramicin may also be used in combination with virginiamycin as in § 558.635.

[59 FR 17477, Apr. 13, 1994, as amended at 60 FR 57928, Nov. 24, 1995; 61 FR 29481, June 11, 1996; 61 FR 43451, Aug. 23, 1996; 61 FR 66584, Dec. 18, 1996; 62 FR 66985, Dec. 23, 1997; 64 FR 48296, Sept. 3, 1999; 66 FR 47964, Sept. 17, 2001; 69 FR 13221, Mar. 22, 2004; 70 FR 41961, July 21, 2005; 73 FR 812, Jan. 4, 2008; 74 FR 41631, Aug. 18, 2009; 79 FR 10983, Feb. 27, 2014; 79 FR 13546, Mar. 11, 2014; 81 FR 17609, Mar. 30, 2016; 81 FR 95013, Dec. 27, 2016; 86 FR 14826, Mar. 19, 2021; 87 FR 17948, Mar. 29, 2022]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5895 Continuous ventilator. ( a ) *Identification.* A continuous ventilator (respirator) is a device intended to mechanically control or assist patient breathing by delivering a predetermined percentage of oxygen in the breathing gas. Adult, pediatric, and neonatal ventilators are included in this generic type of device.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7720 Prothrombin consumption test. ( a ) *Identification.* A prothrombin consumption tests is a device that measures the patient's capacity to generate thromboplastin in the coagulation process. The test also is an indirect indicator of qualitative or quantitative platelet abnormalities. It is a screening test for thrombocytopenia (decreased number of blood platelets) and hemophilia A and B.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60625, Sept. 12, 1980, as amended at 84 FR 71800, Dec. 30, 2019]
§ 70.50 Application of the cancer clause of section 721 of the act. ( a ) *Color additives that may be ingested.* Whenever ( 1 ) the scientific data before the Commissioner (either the reports from the scientific literature or the results of biological testing) suggest the possibility that the color additive including its components or impurities has induced cancer when ingested by man or animal; or
( 2 ) tests which are appropriate for the evaluation of the safety of additives in food suggest that the color additive, including its components or impurities, induces cancer in man or animal, the Commissioner shall determine whether, based on the judgment of appropriately qualified scientists, cancer has been induced and whether the color additive, including its components or impurities, was the causative substance. If it is his judgment that the data do not establish these facts, the cancer clause is not applicable; and if the data considered as a whole establish that the color additive will be safe under the conditions that can be specified in the applicable regulation, it may be listed for such use. But if in the judgment of the Commissioner, based on information from qualified scientists, cancer has been induced, no regulation may issue which permits its use.
( b ) *Color additives that will not be ingested.* Whenever the scientific data before the Commissioner suggest the possibility that the color additive, including its components or impurities, has induced cancer in man or animals by routes other than ingestion, the Commissioner shall determine whether, based on the judgment of appropriately qualified scientists, the test suggesting the possibility of carcinogenesis is appropriate for the evaluation of the color additive for a use which does not involve ingestion, cancer has been induced, and the color additive, including its components or impurities, was the causative substance. If it is his judgment that the data do not establish these facts, the cancer clause is not applicable to preclude external drug and cosmetic uses, and if the data as a whole establish that the color additive will be safe under conditions that can be specified in the regulations, it may be listed for such use. But if, in the judgment of the Commissioner, based on information from qualified scientists, the test is an appropriate one for the consideration of safety for the proposed external use, and cancer has been induced by the color additive, including its components or impurities, no regulation may issue which permits its use in external drugs and cosmetics.
( c ) *Color additives for use as an ingredient of feed for animals that are raised for food production.* Color additives that are an ingredient of the feed for animals raised for food production and that have the potential to contaminate human food with residues whose consumption could present a risk of cancer to people must satisfy the requirements of subpart E of part 500 of this chapter.
[42 FR 15636, Mar. 22, 1977, as amended at 43 FR 22675, May 26, 1978; 52 FR 49586, Dec. 31, 1987]
Exhibit 31

Certifications

I, Richard Simpson, certify that:

1.I have reviewed this report on Form 10-K and all reports on Form 10-D required to be filed in respect of the period covered by this report on Form 10-K of Citigroup Commercial Mortgage Trust 2015-P1 (the “Exchange Act periodic reports”);

2.Based on my knowledge, the Exchange Act periodic reports, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, all of the distribution, servicing and other information required to be provided under Form 10-D for the period covered by this report is included in the Exchange Act periodic reports;

4.Based on my knowledge and the servicer compliance statement(s) required in this report under Item 1123 of Regulation AB, and except as disclosed in the Exchange Act periodic reports, the servicers have fulfilled their obligations under the servicing agreements in all material respects; and

5.All of the reports on assessment of compliance with servicing criteria for asset-backed securities and their related attestation reports on assessment of compliance with servicing criteria for asset-backed securities required to be included in this report in accordance with Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to this report, except as otherwise disclosed in this report.  Any material instances of noncompliance described in such reports have been disclosed in this report on Form 10-K.

In giving the certifications above, I have reasonably relied on information provided to me by the following unaffiliated parties: Wells Fargo Bank, National Association; LNR Partners, LLC; Park Bridge Lender Services LLC; CoreLogic Commercial Real Estate Services, Inc.; National Tax Search, LLC; Berkadia Commercial Mortgage LLC; Principal Real Estate Investors, LLC; Berkeley Point Capital LLC; and Midland Loan Services, a Division of PNC Bank, National Association.

Date:March 30, 2020

|  | /s/ Richard Simpson ___________________Richard SimpsonPresident, Citigroup Commercial Mortgage Securities Inc.(senior officer in charge of securitization of the depositor) |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

CGCMT 2015-P1 Certifications
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4470 Surgeon's gloving cream. ( a ) *Identification.* Surgeon's gloving cream is an ointment intended to be used to lubricate the user's hand before putting on a surgeon's glove.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38803, July 25, 2001]
§ 876.5100 Suprapubic catheter accessories. ( a ) *Identification.* Suprapubic catheter accessories are manual devices that are used to facilitate the placement of a suprapubic catheter. This generic type of device includes the introducer, access dilator, and peel-away sheath.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[84 FR 14870, Apr. 12, 2019]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Swift Energy
Income  Partners  1986-D,  Ltd.'s balance sheet and statement of operations con-
tained in its Form 10-Q for the quarter  ended June 30, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   JUN-30-1997
<CASH>                                         1,041
<SECURITIES>                                   0
<RECEIVABLES>                                  198,017
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               199,058
<PP&E>                                         12,898,885
<DEPRECIATION>                                 (10,608,332)
<TOTAL-ASSETS>                                 2,489,611
<CURRENT-LIABILITIES>                          81,884
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     2,282,446
<TOTAL-LIABILITY-AND-EQUITY>                   2,489,611
<SALES>                                        260,279
<TOTAL-REVENUES>                               263,976
<CGS>                                          0
<TOTAL-COSTS>                                  187,670<F1>
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                13,458
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            13,458
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   13,458
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
<FN>
<F1>Includes  lease  operating  expenses,  production  taxes  and  depreciation,
depletion and  amortization  expense.  Excludes general and  administrative  and
interest expense.
</FN>
        



</TABLE>
_____________ No. 95-2514WM

_____________ United States of America, * * Appellee, * Appeal from the United States * District Court for the Western v. * District of Missouri. * Deon Love, * [UNPUBLISHED] * Appellant. *

_____________ Submitted: December 7, 1995 Filed: December 13, 1995

_____________ Before FAGG, LOKEN, and MORRIS SHEPPARD ARNOLD, Circuit Judges.

_____________ PER CURIAM. Deon Love appeals the drug-related sentence imposed by the district court under the sentencing guidelines. Love contends he was entitled to a reduction to a sentencing range of 151-188 mon ths because of Love's role in the offense. We disagree. At sentencing, the district court granted the government's moti on for a downward departure and sentenced Love to 84 mo nths imprisonment and five years supervised release. Because Love's 84-month sentence represents a downward departure from the guideline range sought by Love, Love's sentenc e is not reviewable. See United States v. Baker , 64 F.3d 439, 441 (8th Cir. 1995). We affirm Love's sentence.

### -2- A true copy. Attest: CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                      13,300,000
<SECURITIES>                                         0
<RECEIVABLES>                               21,600,000
<ALLOWANCES>                                         0
<INVENTORY>                                 43,500,000
<CURRENT-ASSETS>                            81,500,000
<PP&E>                                   1,196,500,000
<DEPRECIATION>                           (873,500,000)
<TOTAL-ASSETS>                             419,400,000
<CURRENT-LIABILITIES>                      128,600,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  1,800,000
<COMMON>                                       900,000
<OTHER-SE>                                (64,100,000)
<TOTAL-LIABILITY-AND-EQUITY>               419,400,000
<SALES>                                    104,600,000
<TOTAL-REVENUES>                           104,600,000
<CGS>                                       76,600,000
<TOTAL-COSTS>                              112,100,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                         (3,900,000)<F1>
<INCOME-PRETAX>                           (11,400,000)
<INCOME-TAX>                               (1,800,000)
<INCOME-CONTINUING>                       (13,200,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (16,600,000)
<EPS-BASIC>                                   (0.18)
<EPS-DILUTED>                                   (0.18)
<FN>
<F1>NET OF INTEREST INCOME OF $1.7 MILLION.
</FN>


</TABLE>
39022.

#### JONES v. PETERS *et al.*

Decided September 19, 1961

Rehearing denied October 5, 1961.

*589*Almon, Clien & McGregor, Everett L. Almon,*for plaintiff in error.

*Thomas E. Moran,*contra.

Hall, Judge.

Neither the original petition nor the amended petition alleges the terms of payment or the time the sum owed by the defendant was due to be paid. A petition seeking to recover a sum of money alleged to be due by the defendant to the n-tiff which does not allege that the sum was past due at the time °£ the filing of the petition does not set forth a cause of action. *Five Minute vxdbuwrisia-aT*iítn?, *Ct?._&.*«.<7. 23 Ga. App 641 (99 SE 225).

*Judgment affirmed.*

*Felton, C. J., and Bell, J., concur.*
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheets and statements of operations found on page 2 and 4 of the
Company's Form 10-Q for the year to date, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>                               
<PERIOD-TYPE>                 9-MOS
<FISCAL-YEAR-END>                         DEC-31-1996
<PERIOD-END>                              SEP-30-1997
<CASH>                                      1,961,744
<SECURITIES>                                1,462,463 
<RECEIVABLES>                               1,046,325
<ALLOWANCES>                                        0
<INVENTORY>                                 1,375,189 
<CURRENT-ASSETS>                            6,672,591
<PP&E>                                      4,804,414      
<DEPRECIATION>                                      0
<TOTAL-ASSETS>                             12,043,943
<CURRENT-LIABILITIES>                       1,267,455
<BONDS>                                             0
<COMMON>                                   11,136,042
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<OTHER-SE>                                   (511,214)
<TOTAL-LIABILITY-AND-EQUITY>               12,043,943 
<SALES>                                    10,894,179
<TOTAL-REVENUES>                           10,894,179
<CGS>                                       7,503,863
<TOTAL-COSTS>                               7,503,863
<OTHER-EXPENSES>                            2,882,546
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                                  0
<INCOME-PRETAX>                               661,201
<INCOME-TAX>                                  264,484
<INCOME-CONTINUING>                           396,717
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                  396,717
<EPS-PRIMARY>                                     .04
<EPS-DILUTED>                                     .04

</TABLE>
#### In re AIR CRASH DISASTER NEAR NEW ORLEANS, LOUISIANA ON JULY 9, 1982. Louis Alberto TRIVELLONI-LORENZI and Susana Electra Trivelloni-Lorenzi, Plaintiffs-Appellees, v. PAN AMERICAN WORLD AIRWAYS, INC., et al., Defendants-Appellants. Ernesto Serio PAMPIN LOPEZ, Individually and as Administrator of the Estate of His Deceased Mother Sara E. Lopez De Pampin, Plaintiff-Appellee, v. PAN AMERICAN WORLD AIRWAYS, INC. and United States of America, Defendants-Appellants.

Nos. 84-3832, 84-3833.

United States Court of Appeals, Fifth Circuit.

July 8, 1986.

Deutsch, Kerrigan & Stiles, Francis G. Weller, Frederick R. Bott, Darrell K. Cher*382ry, Robert E. Kerrigan, Jr., New Orleans, La., for defendants-appellants.

Stephen B. Murray, Romualdo Gonzalez, Patricia R. Murray, New Orleans, La., fór plairitiffs-appellees.

Before CLARK, Chief Judge, GEE, RUBIN, REAVLEY, POLITZ, RANDALL, JOHNSON, WILLIAMS, GARWOOD, JOLLY, HIGGINBOTHAM, DAVIS, HILL, and JONES, Circuit Judges.

ON PETITIONS FOR REHEARING AND SUGGESTIONS FOR REHEARING EN BANC

(Opinion May 7, 1986, 5 Cir., 1986, 789 F.2d 1092)

BY THE COURT:

A member of the Court in active service having requested a poll on the suggestion for rehearing en banc and a majority of the judges in active service having voted in favor of granting a rehearing en banc,

IT IS ORDERED that this cause shall be reheard by the Court en banc with oral argument. The Clerk will specify a briefing schedule for the filing of supplemental briefs.